Transgenderism
Conditions
Keywords
transgender persons, hormonal therapy
Brief summary
Cardiovascular diseases are the leading cause of mortality. In women, the prevalence of cardiovascular diseases is lower and the presentation of coronary events often atypical. The lack of evidence is related in part to the methodology of studies not considering sex as an essential biological variable. Hormonal treatment is prescribed in transgender subjects to promote the development of sexual characteristics of the desired sex. Early cardiovascular effects of hormonal treatment have been reported in transgender men, while long-term mortality is higher in transgender women. The aim of this project is to study the effects of gender affirming hormonal treatment on arterial stiffness in young transgender subjects followed at the University Hospital of Nancy.
Interventions
DRUGgender affirming hormonal treatment in transgender men
testosterone enanthate
DRUGgender affirming hormonal treatment in transgender women
GnRH agonists + estrogen
Sponsors
Central Hospital, Nancy, France
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 49 Years
Healthy volunteers
No
Inclusion criteria
* Trasgender subject demanding gender affirming hormonal therapy
Exclusion criteria
* Previous hormonal therapy * Pregnancy * Chronic disease * Cancer * Obesity * Drug abuse * Alcohol * Tabac
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| pulse wave velocity | 24 months | measurement of arterial stiffness |
Outcome results
None listed